All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte and Lilly. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
During the European Hematology Association (EHA) 2025 Congress, June 12–15, 2025, Milan, IT, Yuqin Song presented results from Part 2 of this trial. The primary endpoint was the overall response rate (ORR).1 Key secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. The median follow-up was 15.2 months.1 |
Key learnings |
The primary endpoint was met: the ORR was 64.2%, with a CR rate of 32.8%. The ORR benefit was observed across PTCL subtypes (AITL, 70.3%; PTCL-NOS, 57.1%; ENKTL-NT, 50.0%; ALCL, ALK−, 42.9%; ALCL, ALK+, 50.0%; MEITL, 100%). |
The median DoR, PFS, and OS were 18.7 months, 10.0 months, and not reached, respectively. |
Any-grade TEAEs and Grade ≥3 TEAEs occurred in 92.5% and 61.2% of patients, respectively. The most common Grade ≥3 TEAEs were decreased platelet count (28.4%), decreased neutrophil count (26.9%), decreased WBC count (25.4%), and anemia (23.9%). |
SHR2554 demonstrated efficacy and a manageable safety profile across PTCL subtypes, making it a potentially new therapeutic option for this challenging-to-treat population. A phase III study comparing SHR2554 vs tucidinostat for R/R PTCL is currently ongoing (NCT06122389). |
AITL, angioimmunoblastic T-cell lymphoma; ALCL, ALK-, anaplastic large-cell lymphoma, anaplastic lymphoma kinase-negative; ALCL, ALK+, ALCL, ALK-positive; CR, complete response; DoR, duration of response; EHA, European Hematology Association; ENKTL-NT, extranodal NK/T-cell lymphoma nasal type; EZH2, enhancer of zeste homolog 2; MEITL, monomorphic epitheliotropic intestinal T-cell lymphoma; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PTCL, peripheral T-cell lymphoma; PTCL-NOS, PTCL-not otherwise specified; R/R, relapsed/refractory; TEAE, treatment-emergent adverse event.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with chronic lymphocytic leukemia do you see in a month?